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http://dx.doi.org/10.1016/j.ccell.2014.09.006SUMMARYBlockade of colony-stimulating factor-1 (CSF-1) limits macrophage infiltration and improves response of
mammary carcinomas to chemotherapy. Herein we identify interleukin (IL)-10 expression by macrophages
as the critical mediator of this phenotype. Infiltrating macrophages were the primary source of IL-10 within
tumors, and therapeutic blockade of IL-10 receptor (IL-10R) was equivalent to CSF-1 neutralization in
enhancing primary tumor response to paclitaxel and carboplatin. Improved response to chemotherapy
wasCD8+ T cell-dependent, but IL-10 did not directly suppressCD8+ T cells or altermacrophage polarization.
Instead, IL-10R blockade increased intratumoral dendritic cell expression of IL-12, which was necessary for
improved outcomes. In human breast cancer, expression of IL12A and cytotoxic effector molecules were
predictive of pathological complete response rates to paclitaxel.INTRODUCTION
Tumor-associated macrophages are associated with poor clin-
ical outcome in most carcinomas, with clinical and preclinical
data indicating that this is due largely to macrophage pro-
motion of angiogenesis, local invasion, and increasedmetastatic
capacity (Bingle et al., 2002; Ruffell et al., 2012a). Because
macrophages are highly dependent on the colony-stimulating
factor-1 (CSF-1) and CSF-1 receptor (CSF-1R) pathway for sur-
vival in most tissues (Pollard, 2009), there is significant interest
in therapeutically targeting this pathway. In murine models,
small-molecule inhibitors of CSF-1R induce tumor regressionSignificance
Therapeutics targeting the CSF-1/CSF-1 receptor pathway are
either as monotherapy or in combination with standard-of-care
CSF-1 receptor pathway andmacrophages sustain tumor grow
Herein we report that macrophages infiltrating mammary carci
presses intratumoral dendritic cell production of IL-12 and the
These data reveal a role for the interaction between tumor mac
apy, identify a CSF-1/IL-10/IL-12 cytokine axis for targetable in
for patient selection.
Canin glioblastomamultiforme (Pyonteck et al., 2013), prevent tumor
growth in cervical cancer (Strachan et al., 2013), and partially
delay growth of implanted melanoma cell lines (Mok et al.,
2014). An aCSF-1Rmonoclonal antibody (mAb) has also demon-
strated clinical efficacy in diffuse-type giant tumors, a disease
driven by overexpression of CSF-1 and recruitment of myeloid
cells (Ries et al., 2014).
In themousemammary tumor virus (MMTV)-polyomamiddle T
(PyMT) transgenic model of luminal B-type mammary carci-
noma, tumor infiltration by F4/80+ macrophages parallels dis-
ease progression (DeNardo et al., 2009), and MMTV-PyMT
mice harboring homozygous null mutations in the CSF-1 genecurrently being evaluated clinically in multiple cancer types,
chemotherapy. However, mechanisms by which the CSF-1/
th and/or repress response to cytotoxic therapy are unclear.
nomas are the significant source of IL-10, which in turn sup-
reby limits cytotoxic T cell responses during chemotherapy.
rophages and dendritic cells in mediating response to ther-
tervention, and reveal possible risk stratification biomarkers
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Figure 1. Macrophages Are the Primary Source of IL-10 in Mammary Tumors
(A) Representative images of F4/80 immunoreactivity (left) in mammary tumors from MMTV-PyMT mice treated with IgG1 or aCSF-1 mAb in combination with
PTX. Quantitation of CD11b+F4/80+MHCII+Ly6C macrophages by flow cytometry is shown to the right as a percentage of total live cells. Significance was
determined by an unpaired t test with Welch’s correction, with ***p < 0.001.
(legend continued on next page)
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IL-10 Limits Chemotherapeutic Efficacyexhibit limited tumor angiogenesis, slowed tumor progression,
and inhibited pulmonary metastasis (Lin et al., 2001). Although
therapeutic depletion of macrophages from tumors with mAbs
or small-molecule inhibitors targeting CSF-1 or CSF-1R, respec-
tively, exhibits no efficacy as single agents (DeNardo et al., 2011;
Strachan et al., 2013), administration in combination with stan-
dard-of-care chemotherapy (CTX) significantly slows primary
tumor growth kinetics and diminishes pulmonary metastasis
(DeNardo et al., 2011). On the basis of these data, clinical studies
combining the CSF-1R small-molecule inhibitor PLX3397 and
CTX are currently under way (ClinicalTrials.gov identifiers
NCT01596751 and NCT01525602).
Although macrophages have been found to directly promote
the survival of mammary carcinoma cells in a cathepsin-depen-
dent manner in vitro (Shree et al., 2011), our previous studies
reported that enhanced chemotherapeutic efficacy associated
with CSF-1R inhibition was dependent on cytotoxic CD8+
T cells (DeNardo et al., 2011), thus indicating a role for macro-
phages in suppressing a T cell response during CTX. Several
studies have demonstrated that tumor-associated macro-
phages directly suppress CD8+ T cell activation in vitro (De-
Nardo et al., 2011; Doedens et al., 2010; Movahedi et al.,
2010), and CSF-1R inhibition has been found to enhance
adoptive cell transfer therapy in melanoma models (Mok et al.,
2014). However, the mechanism(s) by which macrophages
suppress antitumor responses, either directly or indirectly in
vivo, remains unclear. Here we sought to inform ongoing clin-
ical trials by delineating functionally significant mechanisms
whereby tumor-infiltrating macrophages suppress CD8+ T cell
responses during CTX.
RESULTS
Macrophages Are the Primary Source of Interleukin-10
in Mammary Carcinomas
To identify the molecular mechanisms by which macrophages
limited response to CTX in mammary carcinomas, we effectively
depleted macrophages through administration of aCSF-1 mAb
in combination with paclitaxel (PTX) in MMTV-PyMT tumor-
bearing mice (Figure 1A) and examined the status of tumor
vasculature (Figures S1A and S1B available online), as well as
expression of immune-related genes in whole tumor tissue (Fig-
ure 1B). Although macrophages promote formation of abnormal
tumor vasculature (Stockmann et al., 2008), we did not observe
changes in density of CD31+ vessels, the ratio of pericytes to
endothelial cells, or extravasation of either doxorubicin or PTX
into mammary tumors, as quantitatively evaluated by immuno-
fluorescence approaches or liquid chromatography-mass spec-(B) Fold change in whole-tissue gene expression in tumors from PTX/aCSF-1 mA
Only significant (p < 0.05; Mann-Whitney test) changes are shown; nR 12 mice
(C) Il10mRNA expression levels from fluorescence-activated cell-sorted stromal p
are normalized to Tbp expression and displayed as mean ± SEM with n = 8 per
(D) Correlation between IL10 expression and various myeloid-associated genes
(E) Detection of IL-10 in human breast cancer by immunohistochemistry. Fourteen
images reflecting low and high staining are displayed.
(F) Immunofluorescent staining for IL-10, CD163, and DNA using Hoescht 3334
samples are displayed.
See also Figure S1.
Cantrometry, respectively (Figures S1C and S1D), thus indicating
that improved responses toCTXwere unlikely linked to improved
tumor hemodynamics. Instead, gene expression data revealed
decreases in several myeloid-associated genes relative to con-
trol tissue, including Il1a, Il10, Nos2, Cxcl10, Ccl3, and Ccr2,
and, inversely, increased expression of Gzmb, Ccl5, Cd8a, and
Il12a, consistent with our previous report of a role for CD8+
T cells in mediating response to CTX following CSF-1R inhibition
(DeNardo et al., 2011). We found no change in genes reflecting a
CD4/TH1 response (Ifng, Tbx21, and Cd4).
Of the mRNAs exhibiting reduced expression following aCSF-
1 mAb therapy, Il10 is the most strongly associated with an es-
tablished immunosuppressive role in vivo (Moore et al., 2001).
We confirmed macrophages as the primary source of interleukin
(IL)-10 in untreated mammary carcinomas by evaluating fluores-
cence-activated cell-sorted epithelial versus stromal cell popu-
lations (Figures S1E and S1F). Il10 expression was limited to
CD45+ leukocytes, with expression observed in Ly6C+ mono-
cytes, CD11b+ dendritic cells (DCs), CD4+ T cells, and F4/80+
macrophages (Figure 1C). Macrophage expression of Il10 was
approximately 10-fold higher than other leukocyte populations,
with an additional 1.5-fold average increase in expression
by MHCIILO versus MHCIIHI macrophages. We further char-
acterized the MHCIIHI and MHCIILO macrophage subsets and
found that both were effectively depleted by aCSF-1 mAb
treatment (Figures S1G–S1I), and exhibited similar nuclear
morphology in cytospins (Figure S1J); however, MHCIILOmacro-
phages displayed increased expression of several markers
associated with TH2/M2-type programming at both the protein
(MSR1, MRC1, and IL4Ra) (Figure S1K) and mRNA (Cd163,
Msr1, Mrc1, Il4ra, Arg1, and Ptgs2) levels (Figure S1L).
On the basis of high expression of Il10 by macrophages, and
its partial correlation with M2/TH2-type biomarkers in mammary
carcinomas, we evaluated expression of IL10 in human breast
cancer samples from The Cancer Genome Atlas (TCGA) data
set against genes associated with presence of myeloid cells
(CSF1R, CD14, and CD68) or macrophage polarization (MSR1,
MRC1, and CD163). We identified significant correlation be-
tween these mRNAs, with the most significant correlation occur-
ring for MSR1 and CD163 (Figure 1D). IL10 expression did not
correlate with FOXP3 expression (data not shown), despite re-
ports of regulatory T (TReg) cells being a critical source of IL-10
in some murine tumor models (Stewart et al., 2013). Because
the association between IL10 expression and macrophages
markers was relatively weak (R < 0.23), we also evaluated the
presence of IL-10 protein by immunohistochemistry in human
breast cancer samples. In accordance with the gene expression
correlations, we observed high expression within stromal cells,b-treated mice determined by real-time PCR using a 96-gene immune array.
per group.
opulations isolated from untreated mice as determined by real time PCR. Data
cell type. MØ, macrophage; mono, monocyte.
in human breast cancer samples from the TCGA data set (n = 1,161).
CTX-naive and 9 CTX-treated patient samples were evaluated. Representative
2 in human breast cancer. Representative images from one of three patient
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Figure 2. IL-10 Receptor Blockade Im-
proves Response to PTX
(A) Relative tumor volume in MMTV-PyMT mice
following treatment with IgG1, aCSF-1 mAb,
aIL-10R mAb, PTX, or a combination thereof.
Dosing strategy is displayed at top. Data are dis-
played asmean ± SEM,with nR 9mice per group.
Significance was determined by two-way ANOVA,
with ***p < 0.001.
(B) Survival of mice bearing orthotopic PyMT-
derived tumor explant tumors following treatment
with IgG1, aCSF-1 mAb, aIL-10R mAb, PTX, or a
combination thereof. Significance was determined
by log rank, with **p < 0.01 and ***p < 0.001; nR
12 mice per group.
(C) Relative tumor volume in MMTV-PyMT mice
following treatment with IgG1 or aIL-10R mAb in
combination with carboplatin (CBDCA). Dosing
strategy is displayed at top. Data are displayed as
mean ± SEM, with n R 5 mice per group. Signifi-
cance was determined by two-way ANOVA, with
*p < 0.05.
(D) Relative tumor volume in C3(1)-TAg mice
following treatment with IgG1, aCSF-1 mAb, or
aIL-10R mAb in combination with PTX. Dosing
strategy is displayed at top. Data are displayed as
mean ± SEM, with n R 8 mice per group. Signifi-
cance was determined by two-way ANOVA, with
***p < 0.001.
(E) Representative hematoxylin and eosin sections
of lungs taken from animals treated with PTX
alone or in combination with aCSF-1 mAb or aIL-
10R mAb.
(F) The number of metastastic foci per lung in each
treatment group from (A). Data are displayed as
mean ± SEM, with n R 9 mice per group. Signifi-
cance was determined by an unpaired t test with
Welch’s correction, with *p < 0.05 and **p < 0.01.
(G) The average size of metastatic foci in
each treatment group. Data are displayed as
mean ± SEM, with n R 9 mice per group. Signifi-
cance was determined by an unpaired t test with
Welch’s correction with **p < 0.01.
See also Figure S2.
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IL-10 Limits Chemotherapeutic Efficacyincluding CD163+ cells with a myeloid morphology (Figures 1E
and 1F). In contrast to murine tumor tissue, however, we also
observed variable expression within tumor epithelial cells.
Thus, although macrophages, in particular TH2/M2-type macro-
phages, are associated with expression of IL-10 in both murine
mammary carcinomas and human breast cancer, IL-10 produc-
tion within human breast tumors displays increased variability
and complexity.626 Cancer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Inc.Blockade of the IL-10 Receptor
Improves Response to PTX
To examine whether IL-10 was function-
ally relevant for regulating response to
CTX, we treated late-stage tumor-
bearing MMTV-PyMT mice with an IL-10
receptor-blocking mAb (aIL-10R; clone
1B1.3A) prior to and throughout a chemo-
therapeutic regimen of 10 mg/kg PTX
administered every 5 days (Figure 2A).Although neither aIL-10R nor aCSF-1 mAb alone altered tumor
growth kinetics relative to control mice over this time period,
combinatorial PTX with either mAb significantly slowed tumor
growth more effectively than PTX alone, with significant growth
differences occurring following the second dose of PTX. No
additional improvement was observed by combining aCSF-1
and aIL-10R mAbs plus PTX. Using a syngeneic orthotopic
implantable PyMT explant model to evaluate survival, we
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IL-10 Limits Chemotherapeutic Efficacyobserved greater than 2-fold increased survival with either
aCSF-1 mAb/PTX or aIL-10R mAb/PTX (10 days) following initi-
ation of treatment at approximately 1.0 cm in average tumor
diameter, compared with mice treated with PTX alone
(4.5 days) (Figure 2B). MMTV-PyMT mice treated with aIL-10R
mAb also displayed an enhanced response to 50 mg/kg carbo-
platin (CBDCA), with tumors regressing approximately 50%
over the course of treatment (Figure 2C). Using the C3(1)-TAg
model of triple negative mammary carcinogenesis (Deeb et al.,
2007; Maroulakou et al., 1994) we also found significant diminu-
tion of primary tumor growth when combining PTX with either
aCSF-1 or aIL-10R mAbs (Figure 2D; Figures S2A–S2C). Thus,
the ability of IL-10 to limit chemotherapeutic efficacy was not
limited by the type of chemotherapeutic or the subtype of mam-
mary carcinoma being examined.
Regarding pulmonary metastasis, whereas aCSF-1 mAb/PTX
diminished both the number and size of metastastic foci in
MMTV-PyMT mice (Figures 2E–2G), inclusion of aIL-10R mAb
in this regimen yielded no additional benefit. Neither aCSF-1
nor aIL-10R mAbs caused changes to proliferating cells (BrDU
positivity) or cell death (cleaved caspase-3 positivity) in metasta-
tic foci beyond that observed with PTX alone (Figure S2D). Our
interpretation of these data was that whereas CSF-1R-activated
macrophages produce epidermal growth factor (EGF) that in
turn fosters neoplastic mammary epithelial cell invasion and
metastasis (DeNardo et al., 2009; Lin et al., 2001), macro-
phage-derived IL-10 was not involved in programs regulating
metastasis and instead represented a macrophage-dependent
pathway within primary tumors regulating response to CTX.
Because a significant clinical issue theoretically limiting effi-
cacy of CSF-1/CSF-1R-targeted therapy is perceived liver
toxicity due to reduced density of liver Kupffer cells (Strachan
et al., 2013; Wei et al., 2005), we evaluated overall health of
mice enrolled in these studies by several criteria. As expected,
on the basis of a role for Kupffer cells in clearance of serum en-
zymes (Radi et al., 2011), we observed increased serum alkaline
phosphatase, alanine aminotransferase, and aspartate amino-
transferase (Figure S2E) following aCSF-1 mAb therapy. Similar
to what has been reported in nonhuman primates and rodents
(Radi et al., 2011), however, neutralizing CSF-1 alone or in com-
bination yielded no adverse effects on animal health with respect
to liver pathology, weight loss, or renal toxicity (Figures S2F–
S2H). No changes in animal health were noted with aIL-10R
mAb alone or in combination. Thus, targeting of either IL-10R
or CSF-1 improved efficacy of PTX without evidence of acute
toxicity.
Improved Response to PTX Is CD8+ T Cell Dependent
To reveal mechanisms whereby macrophage IL-10 regulated
response to CTX, we examined the presence of T cell popula-
tions in mammary tumors either 2 or 5 days following the
final dose of PTX. Five days after PTX, aCSF-1 mAb or
aCSF-1 mAb/PTX resulted in a small increase in the presence
of CD4+FoxP3+ TReg cells, with no significant changes observed
in CD4+FoxP3 TH cells or CD8
+ T cells (Figure S3A). In contrast,
in mammary tumors evaluated 2 days after PTX, aCSF-1 mAb
and aCSF-1 mAb/PTX therapy resulted in a significant increase
in the relative frequency of CD8+ T cells (Figure 3A). Because
this changemay have resulted from depletion of themajor leuko-Cancyte population, we also evaluated the relative frequency of
CD4+ TH cells and found no significant alteration in most groups
(Figure 3B), resulting in an increased CD8/CD4 T cell ratio within
tumors from aCSF-1 mAb treated animals (Figure 3C). No
changes were observed in CD4+ or CD8+ T cell infiltration
following aIL-10R mAb or aIL-10R mAb/PTX therapy at either
time point. Because increased CD8+ T cell infiltration was
observed with aCSF-1 mAb even in the absence of CTX, and
aCSF-1 mAb/PTX treatment increased mRNA expression of
Gzmb in whole tissue (Figure 1B), we evaluated whether any of
the combinatorial therapies increased the density of granzyme
B (GZMB)-expressing cells, indicative of perhaps a ‘‘better’’
cytotoxic T lymphocyte response. Indeed, both aCSF-1 mAb/
PTX and aIL-10R mAb/PTX therapy increased tumor density of
GZMB-positive cells 2 days after PTX by approximately 1.5-
fold (Figure 3D). Increased presence of GZMB-positive cells
was significant as CD8-depletion prior to PTX ablated improved
outcomes for tumor-bearing mice treated with aIL-10R mAb/
PTX therapy (Figure 3E), similar to our previous finding using a
CSF-1R antagonist (DeNardo et al., 2011).
IL-10 Does Not Influence Macrophage Recruitment,
Polarization, or Function
Because macrophages are known to express IL-10R, we exam-
ined whether IL-10R-blockade was directly influencing macro-
phage presence or function in mammary tumors. Whereas
aCSF-1 mAb led to reduced presence of the two predominant
populations of macrophages (i.e., MHCIIHI and MHCIILO) in
mammary carcinomas (Figures 4A and 4B), blockade of IL-10R
exerted no similar impact (Figures 4A and 4B), as well as having
no effect on the presence of monocytes or neutrophils in tumors
(Figures 4C and 4D).
Because macrophages isolated from MMTV-PyMT mammary
tumors have been reported to exert immunosuppressive activity
ex vivo (DeNardo et al., 2011; Doedens et al., 2010), we next
evaluated the role of IL-10 in mediating this activity. Notably,
the ability of tumor-infiltrating macrophages to suppress splenic
CD8+ T cell proliferation in vitro was largely isolated to the
MHCIILO population (Figures 4E and 4F), correlating with the
presence of MHCIILO macrophages in areas of tumor hypoxia
in situ (Figure 4G) and higher expression of Arg1 (Figure S1L),
similar to models of lung carcinogenesis (Laoui et al., 2014;
Movahedi et al., 2010). That said, neither aIL-10 neutralizing
nor aIL-10R blocking mAb altered the immunosuppressive
capacity of the MHCIIHI or MHCIILO macrophage subset
ex vivo (Figure 4H), and concordantly, addition of IL-10 did
not suppress proliferation or expression of GZMB, interferon
(IFN)-g, or tumor necrosis factor-a by CD8+ splenocytes during
in vitro stimulation (Figures S3B–S3E). On the basis of these
data, and the fact that IL-10 can promote IL-2-induced prolifer-
ation of human (Groux et al., 1998) and mouse CD8+ T cells
(Chen and Zlotnik, 1991) when used at high concentrations
(100 U/ml), we concluded that macrophage-derived IL-10 was
likely regulating CD8+ T cell functionality indirectly. This conclu-
sion was bolstered by the fact that gene expression programs in
macrophages isolated from tumor-bearing mice treated with
aIL-10R mAb were only modestly altered (Figure S4), with the
exception of reduced expression of Socs3, a downstream target
gene of IL-10R signaling (Figure 4I).cer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Inc. 627
Figure 3. Response to aIL-10R/PTX Is CD8+ T Cell Dependent
(A–C) Flow cytometric quantitation of CD3+CD8+ cytotoxic T cells (A), CD3+CD4+FoxP3 TH cells (B), and ratio of CD8
+ to CD4+ TH cells (C) in orthotopic PyMT-
derived tumors 2 days following the second dose of PTX (day 7). Significance was determined by an unpaired t test with Welch’s correction relative to IgG1 or
IgG1/PTX control groups, with *p < 0.05, **p < 0.01, and ***p < 0.001.
(D) Density of GZMB-expressing cells in orthotopic PyMT-derived tumors on day 7 as determined by immunohistochemistry. Data are displayed as mean ± SEM,
with nR 12mice per group. Significance was determined by an unpaired t test withWelch’s correction relative to IgG1 or IgG1/PTX control groups, with *p < 0.05.
Representative images are shown to the right.
(E) Relative mammary tumor volume after 3 rounds of PTX in MMTV-PyMT transgenic mice following treatment with aIL-10R mAb and PTX. CD8+ T cells were
depleted 5 days prior to the first dose of PTX. Data are displayed as mean ± SEM, with nR 5 mice per group. Significance was determined by an unpaired t test
with ***p < 0.001. Polychromatic dot plots displaying CD8+ T cell depletion are shown to the right.
See also Figure S3.
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To address this hypothesis and identify cells infiltrating mam-
mary tumors that potentially were being regulated by macro-
phage-derived IL-10, we evaluated expression patterns of
IL-10R by flow cytometry. Although IL-10R expression has
been observed on colonic epithelium (Denning et al., 2000),
the IL-10-binding subunit of IL-10R (IL-10Ra/IL-10R1) was
restricted to CD45+ leukocytes in mammary tumors, with
the exception of low expression by platelet-derived growth fac-
tor receptor a (PDGFRa)+ fibroblasts (Figure 5A). To identify
select lineages contributing to CD45+ expression, we isolated
leukocyte subsets from mammary tumors as compared with
equivalent populations from spleens (where possible) of non-tu-
mor-bearing mice (Figure 5B). These data revealed significantly
increased expression of IL-10R on CD4+ T cells, Ly6CHI mono-
cytes, macrophages, and DCs, specifically CD103CD11b+ and
CD103+CD11b DC subsets, in tumors, with no significant
increased expression on CD8+ T cells compared with normal
spleen (Figure 5B).
On the basis of these findings, we hypothesized that increased
expression of IL-10R on select myeloid cells indicated their
potential role in regulating functional CD8+ T cell responses628 Cancer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Incfollowing CTX in response to macrophage-derived IL-10.
Because aIL-10R mAb therapy did not alter presence of macro-
phages or monocytes in tumors (Figures 4A–4C) and did not
significantly alter macrophage gene expression programs (Fig-
ure S4), we evaluated the relative percentage of DCs infiltrating
tumors from the various experimental groups. As shown in Fig-
ure 5C, there was an 1.5-fold increase in CD103CD11b+
DCs in tumors from both aCSF-1 mAb/PTX and aIL-10R mAb/
PTX treatment groups, with a further3-fold increased presence
in tumors from aCSF-1 mAb/aIL-10R mAb/PTX-treated mice,
compared with PTX alone. CD103+CD11b DCs were also
increased by either aCSF-1 mAb/PTX or aIL-10R mAb/PTX
treatment, although the effects of aCSF-1 mAb/PTX were more
significant (Figure 5C). Immunofluorescent staining of carci-
nomas revealed that CD103+ cells (reflecting populations of
DCs and CD8+ T cells) were dispersed throughout tumor stroma
in proximity to F4/80+ macrophages, with limited invasion of the
tumor parenchyma (Figure 5D). Although the density of CD103+
cells was increased by aCSF-1 mAb/PTX treatment, their local-
ization appeared unchanged (Figure 5D).
Because tumor macrophages and tumor DCs both ex-
press CD11c, albeit with higher surface expression by DCs.
Figure 4. IL-10 Does Not Influence
Macrophage Recruitment, Polarization, or
Function
(A–D) Percentage of total CD45+ cells in mammary
tumors composed of CD11b+F4/80+MHCIIHI
Ly6C macrophages (A), CD11b+F4/80+MHCIILO
Ly6C macrophages (B), CD11b+F480-Ly6G
monocytes (C), and CD11b+F4/80Ly6G+ neu-
trophils (D). Data were generated by flow
cytometry. Significance was determined by an
unpaired t test with Welch’s correction relative to
IgG1 or IgG1/PTX control groups, with *p < 0.05,
**p < 0.01, and ***p < 0.001.
(E) Representative histograms displaying cell trace
fluorescence of CD8+ splenic T cells stimulated
with aCD3/aCD28 for 60 hr either alone (red) or
cocultured (blue) at a 1:1 ratio with fluorescence-
activated cell-sorted MHCIIHI or MHCIILO macro-
phages from mammary carcinomas.
(F) Fold expansion of dividing CD8+ T cells (repli-
cation index) is displayed at various ratios of CD8+
T cells to macrophages as described in (E). One of
two experiments is shown, with samples assayed
in triplicate. Data are displayed as mean ± SEM.
(G) Detection of hydroxyprobe (pimonidazole)
by intracellular staining of tumor-associated
macrophages. Significance was determined by an
unpaired t test with Welch’s correction, with ***p <
0.001.
(H) Representative histograms displaying cell
trace fluorescence of CD8+ splenic T cells as
described in (E), with addition of 10 mg/ml aIL-10R
or aIL-10 mAb added at the start of the incubation
period. One of two experiments is shown.
(I) Socs3 expression in MHCIIHI and MHCIILO
tumor macrophage subsets determined by real-
time PCR, with data analyzed by comparative
threshold cycle method using Tbp as a reference
gene. Significance was determined by Mann-
Whitney test, with *p < 0.05 and **p < 0.01.
See also Figure S4.
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IL-10 Limits Chemotherapeutic Efficacy(Figure S1K), we fluorescence-activated cell-sorted tumor mac-
rophages, DCs, monocytes, and neutrophils to affirm the correct
populations had been isolated (Figure S5). Confirming our gating
strategy, CD11b+ and CD103+ DCs displayed preferential
expression of DC transcription factors (e.g., Zbtb46, Ciita, and
Pvrl1) and surface markers (e.g., Ccr7, Flt3, Notch2, and
Cd26) compared with either MHCIIHI or MHCIILO macrophage
populations.Cancer Cell 26, 623–637, NIL-10 Represses IL-12 Expression
by DCs
Along with the increase in DC infiltration
observed following either aIL-10R mAb/
PTX or aCSF-1 mAb/PTX therapy (Fig-
ure 5C), we noted an almost 4-fold
increase in Il12a expression in tumors
from aCSF-1 mAb/PTX-treated mice
(Figure 1B). Because CD8+ T cells in
MMTV-PyMT mammary tumors ex-
pressed both subunits of the IL-12 recep-
tor (Figures S6A and S6B), and IL-12 is
known to enhance CD8+ T cell prolifera-tion and effector function (Trinchieri, 2003), we investigated a
possible role for IL-10 in regulating IL-12 production by DCs
and thereby influencing CD8+ T cell responses during CTX. To
evaluate this, we first examined mRNA expression of the IL-12
subunits in sorted leukocyte populations. In mammary tumors
from untreated mice, expression of Il12a mRNA was observed
in most populations; however, mRNA expression of the p40
subunit of IL-12 (Il12b) was limited to DCs and macrophagesovember 10, 2014 ª2014 Elsevier Inc. 629
Figure 5. Expression of IL-10 Receptor by Tumor DCs
(A) Flow cytometric analysis of IL-10R surface expression for EpCAM+ epithelial cells, CD31+ endothelial cells, PDGFRa+ fibroblasts, or CD45+ leukocytes in
untreated MMTV-PyMT mice at end stage (>100 days). Fluorescence minus one (FMO) controls are shown in gray for each histogram. Representative data from
one of three animals are shown.
(B) Surface expression of IL-10Rmeasured bymean fluorescence intensity (MFI) minus background in various leukocyte populations frommammary tumors from
MMTV-PyMT mice compared with similar populations in the spleens of non-tumor-bearing animals. Data are displayed as mean ± SEM, with n = 3 mice per
group. Significance was determined by an unpaired t test compared with the spleen, with *p < 0.05, **p < 0.01, and ***p < 0.001.
(C) Flow cytometric analysis of CD11c+F4/80MHCII+CD103CD11b+ DCs (left) or CD11c+F4/80MHCII+ CD11bCD103+ DCs (right) in tumors from theMMTV-
PyMT animals shown in Figure 2A. Significance was determined by an unpaired t test relative to IgG1 or IgG1/PTX control groups, with *p < 0.05, **p < 0.01, and
***p < 0.001.
(D) Localization of F4/80+ macrophages and CD103+ leukocytes within the tumor stroma of MMTV-PyMT tumors via immunofluorescent staining of serial
sections. Representative images from one of three animals are displayed for both groups.
See also Figure S5.
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IL-10 Limits Chemotherapeutic Efficacy(Figure 6A). Thus, although multiple leukocytes expressed Il12a
mRNA, only DCs and macrophages appeared primed to pro-
duce IL-12. Indeed, IL-12p40 protein was only detectable by
intracellular flow cytometry in a small population of tumor-asso-
ciated CD103+ DCs (Figure 6B), the cell type expressing the
highest levels of Il12b mRNA.
IL-10 regulates IL-12 production by macrophages and DCs
in vitro, depending on the type and kinetics of stimulation (D’An-630 Cancer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Incdrea et al., 1995; Koch et al., 1996). We thus affirmed that
preincubation with IL-10 prevented IFN-g/lipopolysaccharide
(LPS)- and aCD40/LPS-induced production of IL-12p70 by
FLT3-ligand matured bone marrow-derived DCs (BMDCs) (Fig-
ure 6C). This regulation occurred at the level of mRNA expres-
sion, as IL-10 prevented upregulation of Il12a mRNA following
aCD40/LPS stimulation (Figure 6D) and upregulation of Il12b
mRNA (Figure 6E) and the corresponding IL-12p40 protein.
Cancer Cell
IL-10 Limits Chemotherapeutic Efficacy(Figure S6C) following stimulation by any combination of IFN-g,
LPS, or aCD40. Although IL-10 can induce downregulation of
some Toll-like receptor (TLR) signaling components (Kno¨dler
et al., 2009), IL-10’s capacity to suppress IL-12 expression
was not dependent on suppressed DC activation, as CD86
expression was only mildly reduced by IL-10 during stimulation
with IFN-g/aCD40 or aCD40/LPS stimulation (Figure S6D).
Because these data indicated that IL-10 regulated IL-12
expression at the mRNA level in vitro, we isolated macrophages
and DCs from mammary tumors 2 days following the second
dose of PTX (day 7) to determine whether IL-10 was functionally
regulating IL-12 expression in myeloid cells in vivo. Consistent
with our previous findings (Figure S4), aIL-10RmAb/PTX therapy
did not alter expression of either gene in isolated macrophages
(Figure 6F). In both CD103CD11b+ and CD103+CD11b DC
populations, however, aIL-10R mAb/PTX therapy increased
expression of Il12a, with Il12b expression also enhanced in
CD103+CD11b DCs (Figure 6F). The upregulation of Il12b and
detection of IL-12p40 at the protein level in CD103+CD11b
DCs indicates that these may be the critical source of IL-12
within mammary tumors; however, as IL-12p40 is produced in
excess of IL-12p35, this is not definitive.
To evaluate whether IL-12 was functionally significant with
regard to the enhanced CD8-dependent responses observed
in either aIL-10R mAb/PTX or aCSF-1 mAb/PTX-treated exper-
imental groups, late-stage MMTV-PyMT mice were treated with
a neutralizing antibody against either IL-12p40 (recognizing
IL-12 and IL-23) or IL-12p70 (recognizing only IL-12) prior to
administration of PTX. Although neither aIL-12p40 mAb nor
aIL-12p70 mAb altered the response of tumors to PTX alone
(Figure 6G), both neutralizing mAbs blocked the improved
response to PTX observed following aIL-10R mAb therapy (Fig-
ure 6G). Furthermore, consistent with our finding that macro-
phages were the primary source of IL-10 in mammary tumors
(Figure 1), both IL-12 neutralizing antibodies also reversed the
improved response to PTX observed following treatment with
aCSF-1 mAb (Figure 6G).
IL12A Expression Correlates with Increased Pathologic
Complete Response in Breast Cancer Patients
On the basis of these data indicating a significant role for IL-12 in
mediating CD8+ T cells’ responses to PTX in mammary carci-
nomas, we next evaluated whether IL12A or IL12BmRNA levels
correlated with presence of DCs (Figure 7A) in human breast
cancers using the TCGA data set (The Cancer Genome Atlas
Network, 2012). Interestingly, only IL12A correlated with expres-
sion of transcription factors associated with DCs (CIITA) or the
human equivalent of the CD103+ DC subset (BATF3, IRF8).
Expression of IL12A, but not IL12B, was also associated with
evidence of a cytotoxic T cell response in these samples, as
seen by a correlation with GZMB, CD8A, and IFNG expression
(Figure 7B). On the basis of these associations, we next evalu-
ated two published data sets annotated for pathologic complete
response (pCR) following treatment with CTX (Hess et al., 2006;
Tabchy et al., 2010). Here, high expression of IL12A, along with
the DC transcription factors and cytotoxic effector molecules, all
were associated with an improved rate of pCR, with an 2-fold
increase in the response rate observed for many of the genes
(Figure 7C). Taken together, these results indicate an importantCancytokine axis in breast cancers wherein macrophage-derived
IL-10 suppresses IL-12 production by DCs during CTX, thereby
limiting cytotoxic CD8+ T cell responses in carcinomas (Figure 8).
Blockade of either the IL-10/IL-10R pathway or the CSF-1/CSF-
1R pathway thus improves response to CTX and increases sur-
vival of tumor-bearing mice.
DISCUSSION
Herein we describe an interaction between macrophages and
DCs in mammary tumor microenvironments, wherein macro-
phage-derived IL-10 indirectly blunts CD8+ T cell responses
by inhibiting DC production of IL-12 following CTX. Tumor-
associated macrophages have long been described to possess
an immunosuppressive phenotype (Mantovani et al., 2002),
but the in vivo relevance of this phenotype has largely been
inferred. Direct suppression by immature myeloid cells is usually
linked to metabolism of L-arginine or production of free radicals
(Gabrilovich and Nagaraj, 2009). Supporting a role for these
pathways in macrophage-mediated suppression, hypoxia pro-
motes macrophage suppressive capacity and induces expres-
sion of arginase-1 (Doedens et al., 2010), macrophages can
suppress T cell proliferation through L-arginine depletion (Rodri-
guez et al., 2003), and, as reported herein, MHCIILO macro-
phages exhibit tropism for hypoxic regions and exhibit
enhanced suppressive capacity. However, the degree to which
nutrient depletion in a closed in vitro system reflects the tumor
microenvironment is unclear, and other studies have found that
MHCIILO macrophages from implanted lung carcinoma models
(Movahedi et al., 2010) and macrophages from human ovarian
carcinoma ascites (Kryczek et al., 2006) suppress T cell prolifer-
ation independent of arginase and nitric oxide synthase activity.
Human macrophages have instead been found to directly sup-
press T cell responses through programmed death-ligand 1 in
hepatocellular carcinoma (Kuang et al., 2009) and B7-H4 in
ovarian carcinoma (Kryczek et al., 2006), and possibly indirectly
through TReg cell recruitment through CCL22 (Curiel et al.,
2004). Along with these studies, data presented herein describe
a functional role for macrophages in mediating immune sup-
pression within tumors, and ascribe this role to suppression of
DC function.
The drivers of Il10 expression by tumor macrophages are un-
clear. In general, Il10 expression by macrophages is thought to
reflect activation by TLR ligands and type I IFN (Saraiva and
O’Garra, 2010). We noted modestly elevated expression of Il10
fromMHCIILO macrophages, but although higher IL-10 secretion
has also been observed in MHCIILO macrophages from im-
planted lung carcinomas (Laoui et al., 2014), there is no evidence
that hypoxia promotes Il10 expression. MHCIILO macrophages
also expressed higher surface levels of IL-4Ra, but we previously
reported that absence of CD4+ T cells did not influence IL-10
production by macrophages despite the ability of both IL-4
and IL-13 to promote IL-10 production in vitro (DeNardo et al.,
2009). Notably, mammary gland macrophages constitutively ex-
pressed Il10 at levels equivalent to that found in tumor macro-
phages, indicating that the homeostatic environment of the
mammary gland is sufficient to promote Il10 expression, without
a requirement for properties of the tumormicroenvironment such
as inflammation or hypoxia.cer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Inc. 631
Figure 6. Response to PTX Is Dependent on IL-12 Expression by DCs
(A) Il12a or Il12b mRNA expression levels in fluorescence-activated cell-sorted leukocytes from mammary tumors of MMTV-PyMT mice as determined by real-
time PCR. Data are normalized to Tbp expression and displayed as mean ± SEM, with n = 8 per cell type.
(B) Detection of IL-12p40 by intracellular flow cytometry in tumor leukocytes following in vivo administration of brefeldin A. Representative data from one of two
animals are shown.
(C) Production of IL-12p70 by BMDCs as measured by ELISA following 24 hr stimulation with IFN-g/LPS, IFN-g/aCD40, or aCD40/LPS. Cells were pretreated for
24 hr with 1 or 10 U/ml of IL-10 prior to stimulation.
(D and E) Expression of Il12a (D) or Il12b (E) mRNA by BMDCs as measured by RT-PCR. Cells were pretreated for 24 hr with 10 U/ml of IL-10 prior to stimulation.
For (C) to (E), data are displayed asmean ± SEM, samples were assayed in quadruplicate, and one of two representative experiments is shown. Significance was
determined by an unpaired t test relative the control group, with *p < 0.05, **p < 0.01, and ***p < 0.001.
(F) Il12a or Il12b mRNA expression levels in fluorescence-activated cell-sorted MØ and DC populations from mammary tumors of MMTV-PyMT mice 2 days
following the second dose of PTX (day 7) in combination with aIL-10R mAb. Data are normalized to Tbp expression and displayed as mean ± SEM, with nR 4
mice per cell type. Significance determined by a Mann-Whitney test, with *p < 0.05 and **p < 0.01.
(legend continued on next page)
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IL-10 Limits Chemotherapeutic EfficacyIL-10 has the potential to be expressed by most leukocyte
populations (Saraiva and O’Garra, 2010), as well as by normal
and malignant epithelial cells (O’Garra et al., 2008). Despite
this extensive expression capacity, IL-10 production specif-
ically by TReg cells is critical for maintaining tolerance in the
colon (Saraiva and O’Garra, 2010), limiting TH17 inflammation
in tumors (Stewart et al., 2013), and suppressing polyp forma-
tion (Dennis et al., 2013). In contrast to the colon, we found
that in mammary carcinomas, macrophages expressed the
highest level of Il10 mRNA, with 10-fold lower expression
observed in other leukocytes, and no expression observed
by tumor epithelia. As the dominant immune population in
murine mammary tumors, macrophages are thus the critical
source of IL-10.
In human breast cancer, we similarly found no association
between FOXP3 and IL10 expression but rather observed a cor-
relation between IL10 expression and genes associated with
either the presence (CSF1R, CD14, CD68) or polarization
(CD163, MSR1) of macrophages. With no evidence of toxicity
and the potential to simultaneously block multiple pro-tumori-
genic macrophage pathways, targeting of the CSF-1/CSF-1R
pathway continues to be an attractive therapeutic approach.
That said, the increased diversity of leukocytic infiltrates in hu-
man breast cancer (Ruffell et al., 2012b), and our observation
that breast tumor epithelial cells expressed IL-10, argues that
neutralizing the effects of IL-10 in human breast cancer may
require more selective targeting to maximize a cytotoxic T cell
response during CTX. This could take the form of a human aIL-
10R blocking antibody, or kinase inhibitors against downstream
IL-10R signaling components such as Janus kinase 1 or Signal
transducer and activator of transcription 3. It might also be
possible to enhance chemotherapeutic efficacy by directly acti-
vating myeloid cells to produce increased levels of IL-12, either
alone or in combination with IL-10R antagonists. Although
toxicity resulting from systemic myeloid activation is a concern,
it is promising to note that a relatively safe CD40 agonist is in
clinical trials (Beatty et al., 2013).
IL-10 is often referred to as a pleiotropic cytokine, and its dual
role in cancer likely reflects this. Both IL-10 deficiency and IL-10
overexpression can promote antitumor immune responses in
mice (O’Garra et al., 2008). Although IL-10-deficient mice are
resistant to ultraviolet-induced skin carcinogenesis (Loser
et al., 2007), they are also sensitive to skin and colon carcinogen-
esis (Mumm et al., 2011; Sturlan et al., 2001). Some of this
disparity most assuredly reflects the significance of local tumor
microenvironments in sculpting immune responses but also
likely reflects local variations in bioavailable IL-10 (O’Garra
et al., 2008). IL-10 is a potent suppressor of DC activation, with
even 1.0 U/ml largely ablating IL-12 secretion, as well as sup-
pressing DC differentiation in vitro (Allavena et al., 1998). On
the other hand, high concentrations of IL-10 can promote IL-2-
dependent proliferation of CD8+ T cells (Chen and Zlotnik,
1991; Groux et al., 1998), and IL-10 is involved in CD8+ T cell
memory formation in some, but not all, infectionmodels (O’Garra(G) Relative tumor volume after 3 rounds of PTX in MMTV-PyMT transgenic m
neutralizing mAb (aIL-12p40 or aIL-12p70) was administered concurrently every
nificance was determined by an unpaired t test, with *p < 0.05, **p < 0.01, and *
See also Figure S6.
Canet al., 2008). This has led to divergent approaches for targeting
IL-10 as an anticancer therapeutic: blocking IL-10R to enhance
myeloid cell function (Vicari et al., 2002) versus injecting exoge-
nous IL-10 to directly promote an antitumor T cell response
through activation of intratumoral CD8+ T cells (Emmerich
et al., 2012; Mumm et al., 2011). CD8+ T cells in mammary
tumors of MMTV-PyMT did not express IL-10R, indicating that
exogenous IL-10 would likely prove ineffective in this context,
but ongoing clinical studies will determine the validity of this
approach in patients.
Blocking IL-10R has not been used extensively as an
approach for anticancer therapy but has been reported to
induce tumor regression in combination with CpG oligonucleo-
tides in various subcutaneous tumor models, ostensibly through
macrophage/DC activation and increased expression of IL-12
(Guiducci et al., 2005; Vicari et al., 2002). In sharp contrast to
these studies, response to CTX in subcutaneous tumor models
has been found to occur independently of IL-12 and Batf3-
dependent DCs and is instead mediated by an immune cell/
cytokine pathway involving IFN-b, IL-17, and IFN-g, with pro-
duction by CD11b+CD103+ DCs, gd T cells, and CD8+ T cells,
respectively (Kroemer et al., 2013; Ma et al., 2013). The impor-
tance of this pathway for response to CTX has been called into
question using transgenic models of mammary carcinoma, as
these respond to CTX independently of adaptive immune cells,
with the suggestion that this is due to the use of implantable
versus spontaneous tumors (Ciampricotti et al., 2012). We
instead suggest that these differences are due at least partially
to anatomical location. Thus, preventing macrophage infiltration
via aCSF-1 mAbs (or CSF-1R antagonists) or limiting macro-
phage functionality via aIL-10R mAbs, enables CTX and resul-
tant cell death to benefit from productive CD8+ T cell responses
elicited in tumors. However, unlike subcutaneous models, our
data indicate a critical role for IL-12 and possibly CD103+
DCs, again highlighting the role of anatomical location in deter-
mining response to therapy. This concept has been elegantly
demonstrated in a recent study in which subcutaneously
implanted tumors were found to be more sensitive to immuno-
therapy than the same cell lines implanted orthotopically (De-
vaud et al., 2014).
DCs in solid tumors are generally viewed as critical primers of
de novo T cell responses (Chen and Mellman, 2013), and thera-
peutic targeting of DCs has focused on this aspect. Our data do
not definitively demonstrate a role for DCs within mammary
tumors, and systemic suppression of DC function through IL-
10 has been observed (Yang and Lattime, 2003). At the same
time, however, removal of tumor-draining lymph nodes from
mice bearing subcutaneous tumors did not alter response to
CTX (Ma et al., 2013), tertiary lymphoid structures have been
implicated in T cell activity in melanoma (Chen et al., 2013),
and the presence of follicular helper T cells correlates positively
with patient outcome and response to CTX in breast cancer
(Bindea et al., 2013; Gu-Trantien et al., 2013). These studies align
well with our finding that gene expression indicative of a CD8+ice following combination therapy with aCSF-1 mAb or aIL-10R mAb. IL-12
5 days. Data are displayed as mean ± SEM, with nR 5 mice per group. Sig-
**p < 0.001.
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Figure 7. IL12A Expression Correlates with
pCR Rates in Breast Cancer
(A) Linear regression analysis between IL12A or
IL12B expression and various DC-associated
genes (CCR7, IRF8, and CIITA) in human breast
cancer samples from the TCGA data set (n =
1,161).
(B) Linear regression analysis between IL12A or
IL12B expression and various cytotoxic lympho-
cyte-associated genes (GZMB, CD8A, and IFNG)
in human breast cancer samples from the TCGA
data set.
(C) Frequency of pCR in patients separated by
median expression for genes associated with a
cytotoxic T cell response (GZMB, CD8A, and
IFNG) or DCs (IL12A, CIITA, CCR7, and IRF8).
Data reflect a cohort of 379 patients constructed
from two independent data sets. Significance was
determined by a chi-square test.
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IL-10 Limits Chemotherapeutic EfficacyT cell response (GZMB, CD8A, IFNG) or the presence of DCs
(IL12A,CIITA, IRF8) coincideswith improved response to neoad-
juvant CTX, and together hint at the importance of favorable DC
activity within the tumor microenvironment promoting an anti-
tumor immune response to CTX.634 Cancer Cell 26, 623–637, November 10, 2014 ª2014 Elsevier Inc.EXPERIMENTAL PROCEDURES
Ethics Statement
Deidentified human tissue was received from the
University of California, San Francisco (UCSF),
Department of Pathology, with patient consent
forms obtained at the time of tissue acquisition.
Authorization for the use of samples was through
the UCSF Committee on Human Research
(05028310) under ‘‘exempt category 4’’ for individ-
uals receiving deidentified biological specimens.
Animal Care and Use
FVB/n strain background mice harboring the
PyMT transgene under the control of the MMTV
promoter (Guy et al., 1992), and the simian virus
40 large tumor antigen (SV40 TAg) under control
of the rat prostatic steroid binding protein gene
[C3(1)] (Maroulakou et al., 1994), have been previ-
ously described. Implantation of orthotopic mam-
mary tumors was performed as described (De-
Nardo et al., 2011) using single-cell suspensions
from mammary tumors of d80-d85 MMTV-PyMT
transgenic mice combined 1:1 with Matrigel (BD
Biosciences). Treatment schedules were initiated
as indicated in the respective figures. mAbs
(aCSF-1/5A1, aIL-10R/1B1.3A, aCD8/2.43, IgG1/
HRPN, aIL-12p75/R2-9A5, and aIL-12p40/C17.8)
were obtained from BioXCell and were adminis-
tered by intraperitoneal injection at 1.0 mg/mouse,
with follow-up doses of 0.5 mg every 5 days. Clin-
ical grade PTX (Hospira) or carboplatin (Novaplus)
was administered intravenously every 5 days at
10 mg/kg or 50 mg/kg, respectively. Before termi-
nal cardiac perfusion with PBS containing 10 U/ml
of heparin (Sigma-Aldrich), mice were intraperito-
neally injected with 50 mg/kg BrdU (Roche) for
90 min. Resected tissues were either flash frozen
in liquid nitrogen, directly embedded in optimal
cutting temperature (Sakura Finetek) medium afterresection, or incubated overnight in neutral buffered formalin prior to ethanol
dehydration and paraffin embedding. Mice were maintained either within the
UCSF Laboratory for Animal Care barrier facility or the Oregon Health & Sci-
ence University Department of ComparativeMedicine barrier facility. All exper-
iments involving animals were approved by the respective institutional animal
care and use committees.
Figure 8. Model of IL-10 Suppressing IL-12 Production by Dendritic
Cells and Limiting the CD8+ T Cell-Dependent Response to CTX in
Mammary Carcinomas
CD11b+ monocytes are recruited into mammary tumors through increased
CSF-1 gradients largely derived from epithelial cells. Once in tissue or tumor
parenchyma, differentiated macrophages stimulate invasion and metastasis
through EGF, which is induced in response to CSF-1, in combination with IL-4/
IL-13 derived from CD4+ T cells. IL-4/IL-13 also induces expression and/or
activity of cathepsin proteases, directly promoting resistance to CTX-induced
cell death. Macrophages further suppress CTX efficacy by indirectly limiting a
cytotoxic T cell response. Macrophage-derived IL-10 suppresses the ability of
DCs to produce IL-12 during CTX, likely in response to damage-associated
molecular patterns (DAMPs). In the absence of macrophages or IL-10, IL-12
is able to promote a productive CD8+ T cell response, thereby enhancing the
efficacy of CTX.
Cancer Cell
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Statistical analyses were performed using Prism (GraphPad). Statistical signif-
icance was determined via an unpaired t test, an unpaired t test with
Welch’s correction, 2-way analysis of variance (ANOVA), or Mann-Whitney
test as indicated. Heatmaps were generated GENE-E software (http://www.
broadinstitute.org/cancer/software/GENE-E/). All heatmaps are displayed on
a logarithmic scale with values normalized per row, with hierarchical clustering
performed with a 1 minus Pearson correlation. Linear regression analysis in
breast cancer was performed in Prism using the TCGA data set (The Cancer
Genome Atlas Network, 2012). Gene expression data from fine-needle aspi-
rate obtained prior to neoadjuvant CTX in breast cancer patients were
obtained from 2 published data sets (GSE20194 and GSE20271) annotated
for pCR (Hess et al., 2006; Tabchy et al., 2010).
SUPPLEMENTAL INFORMATION
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and six figures and can be found with this article online at http://dx.doi.org/
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